



DAFTAR PUSTAKA

1. Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. *Paediatr Drugs*. 2021 Jul;23(4):331-347. doi: 10.1007/s40272-021-00457-z. Epub 2021 Jul 10. PMID: 34244988; PMCID: PMC8270778.
2. Charras, A., Smith, E. & Hedrich, C. Systemic Lupus Erythematosus in Children and Young People. *Curr Rheumatol Rep* **23**, 20 (2021). <https://doi.org/10.1007/s11926-021-00985-0>
3. Harry O, Yasin S, Brunner H. Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. *J Pediatr*. 2018 May;196:22-30.e2. doi: 10.1016/j.jpeds.2018.01.045.
4. Accapezzato, D.; Caccavale, R.; Paroli, M.P.; Gioia, C.; Nguyen, B.L.; Spadea, L.; Paroli, M. Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. *Int. J. Mol. Sci.* 2023, *24*, 6578. <https://doi.org/10.3390/ijms24076578>
5. Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, Ruiz-Irastorza G. Glucocorticoids in *Systemic Lupus Erythematosus*. Ten Questions and Some Issues. *J Clin Med*. 2020 Aug 21;9(9):2709. doi: 10.3390/jcm9092709. PMID: 32839376; PMCID: PMC7563630.
6. Kwon, S., Hermayer K.L., 2019, Glucocorticoid - Induced Hyperglycemia, *The American Journal of Medical Sciences*, Vol 345, PP 274-277, doi: 10.1097/MAJ.0b013e3182a6a01
7. IDAI, 2020, Diabetes Mellitus pada Anak dan Remaja, *Ikatan Dokter Anak Indonesia UKK Endokrinologi*, idai.or.id
8. Fragoulis GE, Panopoulos S, Mavragani CP. Prediabetes and diabetes mellitus in systemic lupus erythematosus: A systematic review and meta-analysis. *Clin Immunol*. 2021;229:108782.
9. Yuliasih, 2020, *Perkembangan Patogenesis dan Tatalaksana Systemic Lupus Erythematosus*, Airlangga University Press, Surabaya
10. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. *J Autoimmun*. 2019 Jan;96:1-13. doi:10.1016/j.jaut.2018.11.001. Epub 2018 Nov 16. PMID: 30448290; PMCID: PMC6310637.
11. Costagliola G, Mosca M, Migliorini P and Consolini R, 2018, Pediatric Systemic Lupus Erythematosus: Learning From Longer Follow Up to Adulthood. *Front. Pediatr*. 6:144. doi: 10.3389/fped.2018.00144
12. Anugrah, D.A., Patria, S.Y., Satria, C.D., 2022, Linear Growth and systemic glucocorticoid therapy in children with systemic Lupus Erythematosus, Vol 62, P.37-43, DOI: 10.14238/pi62.1.2022.37-43
13. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol*. 2019;71(9):1400–12
14. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019. Update of the EULAR recommendations for the management of systemic lupus erythematosus. *Annals of the Rheumatic Diseases* 2019;**78**:736-745.
15. Barbara, F, et al, 2023, Corticosteroid-induced Hyperglycemia, Vol 42 (11), P68-69, DOI: 10.1097/01.NURSE.0000421388.43735.77
16. Pramesti, D.L., Muktiarti, D., 2021, Perbandingan Kriteria ACR-1997 dan SLICC-2012 dalam Diagnosis Lupus Eritematosis Sistemik pada Anak, *Sari Pediatri*, Vol 22 (6): Pp 386-393
17. Gatto M, Zen M, Iaccarino L, & Doria A. 2019. New therapeutic strategies in systemic lupus erythematosus management. *Nature Reviews Rheumatology*, 15:30-48.
18. Ilias MI, Ali JM, Ismail NZ, Rostenberghe HV, Rahman AA (2017) Pediatric Systemic Lupus Erythematosus (SLE) Manifestations and Outcomes in a Tertiary Hospital. *Lupus*



19. Petri M, Goldman D, Magder LS. Validation of proposed EULAR/ACR SLE classification criteria versus SLICC SLE classification criteria. *Arthritis Rheumatol.* 2018;70(suppl 10).
20. Trindade, V.C., Carneiro-Sampaio, M., Bonfa, E. *et al.* An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. *Pediatr Drugs* **23**, 331–347 (2021). <https://doi.org/10.1007/s40272-021-00457-z>
21. Jin LR, Tao MJ, Zhou J, Xu L, Li Q, Li Z, et al. Metabolic syndrome in systemic lupus erythematosus was closely related to body mass index, blood pressure, blood sugar, blood lipids, and arthritis. *Pak J Med Sci.* 2020;36(6):1220-1227. doi: <https://doi.org/10.12669/pjms.36.6.2093>
22. Konsensus IDAI, 2014, *Diagnosis dan Tata laksana Sindrom Metabolik pada Anak dan Remaja*, IDAI, UKK Nutrisi dan Penyakit Metabolik
23. Pulungan, A.B., Annisa D., Imada S., 2019, Diabetes Melitus Tipe-1 pada Anak: Situasi di Indonesia dan Tatalaksana, *Sari Pediatri*, Vol 20 No. 6, Hal: 392-400
24. Semarawima G, 2018, Status hyperosmolar hiperglikemik, *MEDICINA*, Volume 48, Number 1: 49-53
25. Talat, M., A., Kamal., H., Abdelsalam., M.M., Ramadan, H.S., Said, H.E., Saleh, R.M., 2020, Insulin Resistance in Pediatric Systemic Lupus Erythematosus and Rheumatoid Arthritis, *Suez Canal University Medical Journal*, Vol 23 (2) Pp. 192 – 200
26. Varni, JW., 2023, Scalling and Scoring for the Acute and Standard versions of the Pediatric Quality of Life Inventory (PedsQL™), *Mapi Research Trust*, diakses pada 9 September 2023, <http://www.pedsqil.org/PedsQL-Scoring.pdf>
27. **Blamires J, Foster M, Napier S, Dickinson A.** Experiences and perspectives of children and young people living with childhood-onset systemic lupus erythematosus—An integrative review. *Children.* 2023;10(6):1006
28. Eid R, et al. Health-related quality of life in juvenile-onset systemic lupus erythematosus: a questionnaire-based study. *Matern Child Health J.* 2023;27:1578–88
29. Sag E, Tartaglione A, Ravelli A, et al. Treat to target in juvenile-onset systemic lupus erythematosus: results of an international task force. *Ann Rheum Dis.* 2022;81(4):518-25
30. Bergkamp et al. (2024) – Validasi definisi **childhood Lupus Low Disease Activity State (cLLDAS)** dalam kohort nyata cSLE, memperkuat penggunaan status rendah aktivitas penyakit sebagai target (SLEDAI-LD atau SLEDAI < 4)
31. Semo-Oz N, et al. Adherence to medications by adolescents and young adults with childhood-onset SLE. *Pediatr Rheumatol.* 2022;20(1):70.
32. Vater L, et al. Health literacy and its association with medication adherence and quality of life in childhood-onset systemic lupus erythematosus. *Lupus.* 2024;33(9):1004-11.’
33. **Lim LS, et al.** Nutritional status and dietary intake in children and adolescents with systemic lupus erythematosus. *Lupus Sci Med.* 2022;9(1):e000725.
34. **Kumar P, et al.** Body mass index and metabolic syndrome in pediatric systemic lupus erythematosus. *Clin Rheumatol.* 2023;42(5):1373-81.
35. Heijstek MW, et al. EULAR recommendations for vaccination in paediatric patients with autoimmune rheumatic diseases. *Ann Rheum Dis.* 2022;81(5):706–19.
36. Lim LS, et al. Immunogenicity and safety of HPV vaccination in adolescents with autoimmune rheumatic diseases: a systematic review. *Rheumatology (Oxford).* 2021;60(12):5438–47.
37. Justiz Vaillant AA, Goyal A, Varacallo MA. Systemic Lupus Erythematosus. [Updated 2023 Aug 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK535405/>
38. Rusmil K. Kualitas hidup remaja dengan kondisi penyakit kronis. In: *The 2nd Adolescent Health National Symposia: Current Challenges in Management*. Jakarta: Child Health



Department, School of Medicine, University of Indonesia and Adolescent Task Force Indonesia Pediatric Society; 2013.

39. Pujiastuti E, Fadlyana E, Garna H. Perbandingan masalah psikososial pada remaja obes dan gizi normal menggunakan Pediatric Symptom Checklist (PSC)-17. *Sari Pediatri*. 2016;14:179–84. doi:10.14238/sp14.3.2012.179-84.
40. van Raalte DH, Diamant M. Glucocorticoid-induced diabetes and insulin resistance: Pathophysiology and clinical management. *Nat Rev Endocrinol*. 2014;10(6):293–302.
41. Schäfer M, et al. Mechanisms of glucocorticoid-induced insulin resistance. *Endocr Connect*. 2021;10(10):R181–R197.
42. Liu J, et al. Glucocorticoids and metabolic dysfunction: From molecular mechanisms to clinical implications. *Ther Adv Endocrinol Metab*. 2019;10:2042018819834048.
43. Li JX, Xu J, Chen J, et al. Glucocorticoid-induced hyperglycemia: pathophysiology, risk factors, and management. *Front Endocrinol (Lausanne)*. 2022;13:875109.
44. Shah P, Shelat VG. Steroid-induced hyperglycemia: epidemiology, pathogenesis, and management. *Endocr Pract*. 2022;28(6):642–648.
45. Tavares LC, Caetano LVN, Ianhez M. *Side effects of chronic systemic glucocorticoid therapy: A narrative review of the literature*. *An Bras Dermatol* (Brazilian Annals of Dermatology). 2024; published online May 2023. DOI: 10.1016/j.abd.2023.05.005
46. Bae SC, et al. *EULAR/ACR recommendations for management of SLE*. *Ann Rheum Dis*. 2019.
47. Shah P, et al. *Management of Glucocorticoid-Induced Hyperglycemia*. *Diabetes Metab Syndr Obes*. 2022;15:1401–1416.